Clinical trials: Hepatitis
Bacterial Infections, Virus Diseases
A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)
This study will determine whether three manufacturing lots of V419 (PR5I) induce similar immune responses to all of the antigens contained in V419 when given concomitantly with Prevnar13™ and RotaTeq™.
- Trial name
- NCT01340937
- Testing
- V419, PENTACEL™, Prevnar 13™
- Volunteers
- 2,808 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Hepatitis C, Chronic
Multidisciplinary Support Program in Chronic Hepatitis C
Adherence to antiviral treatment in chronic hepatitis C (CHC) is an important factor to achieve sustained virological response (SVR).
- Trial name
- NCT01850745
- Testing
- Multidisciplinary support program
- Where
- Spain
- Volunteers
- 447 people
- Sponsor
- Parc de Salut Mar
Chronic Hepatitis C
The SIM-SOF Trial for Hepatitis C
Randomized trial of Hepatitis C-genotype 1-infected patients with compensated cirrhosis comparing the standard of care (Peginterferon/Ribavirin/Sofosbuvir) versus the off-label combination of simeprevir+ sofosbuvir without…
- Trial name
- NCT02168361
- Testing
- Pegylated Interferon alfa-2b, Simeprevir, Ribavirin
- Where
- United States
- Volunteers
- 93 people
- Sponsor
- Center For Hepatitis C, Atlanta, GA
Chronic Hepatitis C, Hepatitis C Virus (HCV) Infection
Study of ABT-267 in Treatment Naive Hepatitis C Virus (HCV) Genotype 1 Infected Subjects
The purpose of this study was to assess the safety, pharmacokinetics, and 4-week rapid virologic response (RVR) of 3 different doses of ABT-267 (also known as ombitasvir) in combination with pegylated interferon/ribavirin…
- Trial name
- NCT01314261
- Testing
- ABT-267, Pegylated interferon (pegIFN), Ribavirin (RBV)
- Where
- 11 sites in United States, Puerto Rico
- Volunteers
- 37 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hepatitis C
Safety and Efficacy Study of the Combination Daclatasvir (60 mg), Sofosbuvir (400 mg) and Ribavirin (Weight-based Dosing) for 12 or 16 Weeks in Subjects With Genotype 3 Chronic HCV Infection With or Without Prior Treatment Experience and Advanced Fibrosis or Compensated Cirrhosis
The purpose of the study is to determine if the combination of Daclatasvir, Sofosbuvir and Ribavirin for 12 or 16 weeks is safe and effective in the treatment of Genotype 3 Chronic Hepatitis C (HCV) in patients with advanced…
- Trial name
- NCT02319031
- Testing
- Daclatasvir, Sofosbuvir, Ribavirin
- Where
- 10 sites in Australia, France
- Volunteers
- 53 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis C
A Phase 3 Study to Evaluate Combination Therapy With Daclatasvir and Sofosbuvir in the Treatment of HIV and Hepatitis C Virus Coinfection.
A study of the efficacy and safety of the combination of daclatasvir and sofosbuvir in the treatment of hepatitis C virus and HIV coinfection.
- Trial name
- NCT02032888
- Testing
- Daclatasvir, Sofosbuvir
- Where
- 37 sites in United States
- Volunteers
- 238 people
- Sponsor
- Bristol-Myers Squibb
Chronic Hepatitis C
Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects
The purpose of this study is to assess the effect of BMS-790052 on the pharmacokinetics of Ortho Tri-Cyclen® in healthy female subjects.
- Trial name
- NCT00983957
- Testing
- BMS-790052, Ortho Tri-Cyclen®
- Where
- 3 sites in United States, Canada
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Rift Valley Fever
Safety/Immunogenicity/Genetic Drift of MP-12 Rift Valley Fever Vaccine
This study is to determine if a vaccine for Rift Valley Fever (RVF) is safe to give to humans. The study will examine how well the vaccine (RVF MP-12) stimulates the body's immune response (which fights off infection) and if the…
- Trial name
- MP-12 (NCT00415051)
- Testing
- RVF MP-12
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Drug Use Disorders, Hepatitis C
Community-Based, Client-Centered Prevention Homes to Address the Rural Opioid Epidemic- Aim 3
The goal of this study was to effectively use a client-centered community-based intervention to engage people who inject drugs (PWIDs) in healthcare that helps reduce risky behaviors and lower infectious disease risks.
- Conditions
- Drug Use Disorders, Hepatitis C, Harm Reduction, Opioid-use Disorder
- Trial name
- NCT04268173
- Testing
- Community-Based, Client-Centered Prevention Home
- Where
- 6 sites in United States
- Volunteers
- 343 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Acute Hepatitis C, HIV
To Assess Neuroinflammation and Neurocognitive Function in Patients With Acute Hepatitis C and Chronic HIV Co-Infection
This study plans to evaluate what happens to the brain in patients with HIV and early hepatitis C. The investigators will be comparing 3 groups of individuals: Group 1: Individuals with HIV infection and acute (early) hepatitis C…
- Conditions
- Acute Hepatitis C, HIV, HIV Infections
- Trial name
- NCT00959166
- Testing
- PET scan
- Where
- United Kingdom
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Hepatitis C Infection
Study of SCY-635, Pegasys and Copegus in Hepatitis C
This study will examine the effectiveness of 28 days of triple combination therapy including SCY-635 with peginterferon alfa 2a and ribavirin in reducing serum HCV RNA levels.
- Trial name
- NCT01265511
- Testing
- SCY-635, Pegasys, Copegus
- Where
- 4 sites in United States, Puerto Rico
- Volunteers
- 10 people
- Sponsor
- Scynexis, Inc.
Hepatitis B Vaccine
Immunogenicity of Hepatitis B Vaccination in Hemodialysis Patients
Intramuscular injection of 40 μg hepatitis B vaccine in a standard three-dose schedule or a four-dose schedule is recommended for hemodialysis patients.
- Trial name
- NCT02963714
- Testing
- 60 µg dose hepatitis B vaccine, 20 µg dose hepatitis B vaccine
- Volunteers
- 352 people
- Sponsor
- Suping Wang
Chronic Hepatitis B
Study of Nitazoxanide Compared to Placebo in Subjects With HBeAG-Negative Chronic Hepatitis B
This randomized controlled trial is designed to evaluate safety, effectiveness and pharmacokinetic-pharmacodynamic (PK/PD) relationships associated with three different Nitazoxanide (NTZ) treatment regimens added to Tenofovir…
- Trial name
- NCT03905655
- Testing
- Nitazoxanide
- Where
- Singapore
- Volunteers
- 51 people
- Sponsor
- Romark Laboratories L.C.
Hepatitis C Virus Infection
Study to Investigate Pharmacokinetics, Safety and Efficacy of Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX) Fixed Dose Combination (FDC) in Adolescents and Children With Chronic Hepatitis C Virus (HCV) Infection
The primary objective of this study is to evaluate the steady-state pharmacokinetics (PK) and confirm the age-appropriate dose of sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) fixed-dose combination (FDC) in pediatric…
- Trial name
- NCT03820258
- Testing
- SOF/VEL/VOX
- Where
- 10 sites in Italy, Poland and 1 more
- Volunteers
- 21 people
- Sponsor
- Gilead Sciences
Medication Adherence, Substance Abuse, Intravenous
A Randomized Trial of Vaccine Adherence in Young Injection Drug Users
The purpose of this study is to compare the effects of (a) immunization setting and (b) outreach worker support on young injection drug users' (IDU) adherence to a multiple dose immunization schedule with a combined hepatitis A…
- Conditions
- Medication Adherence, Substance Abuse, Intravenous, Risk Behavior, Hepatitis A
- Trial name
- UFO VAX (NCT00244374)
- Testing
- Hepatitis A & B vaccine, Outreach, AIC
- Where
- United States
- Volunteers
- 546 people
- Sponsor
- University of California, San Francisco
Hepatitis B, Hepatitis A
Long-Term Immune Persistence of GSK Biologicals' Combined Hepatitis A & B Vaccine Injected According to a 0,1,6 Month Schedule
The aim of this study is to evaluate the long-term persistence of hepatitis A and B antibodies at Years 11, 12, 13, 14 and 15 years after subjects received their first dose of a 3 dose vaccination schedule of combined hepatitis…
- Trial name
- NCT00289718
- Testing
- Twinrix™ adult
- Where
- Belgium
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Plasma Cell Disorder
Investigation of the Enhancement of Response to Hepatitis B Vaccine by Lenalidomide in Plasma Cell Dyscrasias
This is a research study to determine if the study drug lenalidomide will increase the body's immune response, which is the body's response against infections or tumors, to hepatitis B vaccine in patients with plasma cell…
- Trial name
- NCT02041325
- Testing
- Lenalidomide
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Boston VA Research Institute, Inc.
Hepatitis C
The Boceprevir and Sildenafil Pharmacokinetics Study
This is a healthy volunteer study looking at the interactions between two drugs: boceprevir and sildenafil. New drugs are being developed to treat people with the chronic viral infection hepatitis C.
- Trial name
- NCT01499498
- Testing
- Sildenafil and Boceprevir
- Where
- United Kingdom
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Imperial College London
Whole Cell Pertussis, Haemophilus Influenzae Type b
Response to GSK Biologicals' Tritanrix-HepB/Hib-MenAC Vacc (4th Dose) at 15-24m & Mencevax ACWY at 24-30m
The purpose of the study is to evaluate the immunogenicity, safety and reactogenicity of a booster dose of DTPw-HBV/Hib-MenAC compared to DTPw-HBV/Hib given to healthy subjects at 15 to 24 months of age primed with 3 doses of…
- Conditions
- Whole Cell Pertussis, Haemophilus Influenzae Type b, Hepatitis B, Diphtheria
- Trial name
- NCT00136604
- Testing
- Tritanrix-HepB/Hib-MenAC, Mencevax ACWY, Tritanrix-HepB/Hiberix
- Where
- 3 sites in Thailand
- Volunteers
- 617 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection
A Study to Evaluate the Efficacy and Safety of Experimental Drugs ABT- 493/ABT-530 in Adults With Chronic Hepatitis C Virus Genotype 1-6 Infection and Human Immunodeficiency Virus -1 Coinfection (EXPEDITION-2)
The purpose of this study is to assess the efficacy and safety of ABT-493/ABT-530 in adults with chronic hepatitis C virus genotype 1-6 infection and human immunodeficiency virus-1 co-infection.
- Conditions
- Hepatitis C Virus Infection, Human Immunodeficiency Virus Infection, Chronic Hepatitis C, Compensated Cirrhosis and Non-cirrhotics
- Trial name
- EXPEDITION-2 (NCT02738138)
- Testing
- ABT-493 coformulated with ABT-530
- Volunteers
- 153 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.